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Abstract 
OBJECTIVE Maternal gestational diabetes mellitus (GDM) has been associated with adverse 
outcomes in the offspring. Growing evidence suggests that the epigenome may play a role, but most 
previous studies have been small and adjusted for few covariates. The current study meta-analyzed 
the association between maternal GDM and cord blood DNA methylation in the Pregnancy and 
Childhood Epigenetics (PACE) consortium. 
RESEARCH DESIGN AND METHODS Seven pregnancy cohorts (3,677 mother-newborn pairs 
[317 with GDM]) contributed results from epigenome-wide association studies, using DNA 
methylation data acquired by the Infinium HumanMethylation450 BeadChip array. Associations 
between GDM and DNA methylation were examined using robust linear regression, with 
adjustment for potential confounders. Fixed-effects meta-analyses were performed using METAL. 
Differentially methylated regions (DMRs) were identified by taking the intersection of results 
obtained using two regional approaches: comb-p and DMRcate. 
RESULTS Two DMRs were identified by both comb-p and DMRcate. Both regions were 
hypomethylated in newborns exposed to GDM in utero compared with control subjects. One DMR 
(chr 1: 248100345–248100614) was located in the OR2L13 promoter, and the other (chr 10: 
135341870–135342620) was located in the gene body of CYP2E1. Individual CpG analyses did not 
reveal any differentially methylated loci based on a false discovery rate–adjusted P value threshold 
of 0.05. 
CONCLUSIONS Maternal GDM was associated with lower cord blood methylation levels within 
two regions, including the promoter of OR2L13, a gene associated with autism spectrum disorder, 
and the gene body of CYP2E1, which is upregulated in type 1 and type 2 diabetes. Future studies 
are needed to understand whether these associations are causal and possible health consequences. 
Introduction 
Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications, with 
prevalence estimates ranging from 2% to 25% depending on the screening and diagnostic criteria 
used and the population examined (1,2). In addition to the adverse pregnancy and delivery 
outcomes associated with GDM, which can include preeclampsia, macrosomia, and shoulder 
dystocia (3), women diagnosed with GDM are four times more likely to have children who develop 
metabolic syndrome later in life and twice as likely to have children who become overweight or 
obese (4). There is also evidence that maternal GDM during pregnancy alters fetal growth 
trajectories (5) and adversely affects neurodevelopment (6,7). Thus, understanding the molecular 
changes related to prenatal exposure to GDM could have widespread implications for children’s 
health. 
One potential mechanism underlying such a diverse array of GDM-associated outcomes is 
epigenetic dysregulation. In support of this, a growing number of studies have observed 
associations between GDM and cord blood DNA methylation patterns (8–17). However, the 
majority of studies have been small (e.g., <100 participants or <30 GDM cases), adjusted for few if 
any covariates, and used lenient or no adjustment for multiple testing (8–10,12–15,17), which may 
have contributed to a lack of replication of results across studies. 
There has therefore been a call for research on GDM and offspring DNA methylation within larger 
studies (18). The current study conducted a meta-analysis of results from epigenome-wide 
association studies (EWAS) of GDM and cord blood DNA methylation patterns from seven cohorts 
participating in the Pregnancy and Childhood Epigenetics (PACE) consortium (19). Additionally, 
we conducted a look-up in our meta-analysis results for CpGs that were previously identified as 
differentially methylated in prior publications. 
Research Design and Methods 
Participating Cohorts 
All cohorts in the PACE consortium (19) were invited to participate in the current meta-analysis. 
Seven cohorts, representing eight countries, participated, contributing a total of 317 GDM case and 
3,360 control subjects (Table 1 and Supplementary Table 1). These cohorts are the Avon 
Longitudinal Study of Parents and Children (ALSPAC), the Genome-Wide Population-Based 
Association Study of Extremely Overweight Young Adults (GOYA), the Healthy Start Study, 
Proyecto Infancia y Medio Ambiente (INMA), the Prediction and Prevention of Preeclampsia and 
Intrauterine Growth Restriction (PREDO) study, Project Viva, and a pooled analysis of three 
cohorts: the Rhea Study (RHEA), the ENVIRonmental influence ON early AGEing 
(ENVIRONAGE) study, and the Piccolipiù study (RHEA/ENVIRONAGE/Piccolipiù). Cohort 
details are described in the Supplementary Data. Each cohort received ethics approval and informed 
consent from participants prior to data collection, and the current meta-analysis was approved by 
the Health Sciences Institutional Review Board of the University of Southern California. 
GDM 
Participants diagnosed with type 1 or type 2 diabetes prior to the index pregnancy were excluded 
from analyses. The criteria used to classify GDM cases are summarized by cohort in Table 1 and 
are also described in more detail in the Supplementary Data. For all cohorts except Piccolipiù, 
GDM was primarily classified based on information that was abstracted from medical records. Due 
to a lack of international consensus, the criteria used to classify GDM differ by country and have 
changed over time. In the U.S. and some European countries, GDM is often diagnosed using a two-
step approach, which entails universal screening with a 50-g glucose challenge test, followed by a 
100-g 3-h oral glucose tolerance test (OGTT) for those who test positive (20). In contrast, some 
European countries have adopted the International Association of Diabetes and Pregnancy Study 
Groups (IADPSG) guidelines (21), which recommend a one-step approach, in which a 75-g 2-h 
OGTT is performed for all women at 24–28 weeks’ gestation. Furthermore, some countries use a 
selective approach and only administer GDM diagnostic tests to women with traditional risk factors. 
GDM cases from the Healthy Start Study, Project Viva, RHEA, and ENVIRONAGE were classified 
based on the two-step approach, using the Carpenter-Coustan criteria (22). GDM cases from 
PREDO were classified based on the IADPSG one-step approach. Piccolipiù identified GDM cases 
based on self-reported questionnaire data collected at delivery, and all but one case was confirmed 
using medical record data (IADPSG one-step approach [21]). GDM cases from INMA were 
diagnosed using a selective screening approach, where women at high risk for GDM were 
administered a glucose challenge test, followed by a diagnostic OGTT, using the Carpenter-Coustan 
criteria (22). GDM cases from ALSPAC and GOYA were diagnosed based on the practices at the 
time in the U.K. and Denmark, respectively, in which diagnostic tests were only performed for 
women 1) at high risk for GDM based on established risk factors or 2) with glycosuria (23,24). 
Given anticipated underreporting of GDM in the medical records, information from telephone 
interviews was also used to classify GDM cases in GOYA. 
Methylation Measurements 
Cord blood DNA was bisulfite converted using a EZ-96 DNA Methylation Kit (Zymo Research 
Corporation, Irvine). Each cohort measured DNA methylation using the Infinium 
HumanMethylation450 BeadChip array (Illumina, San Diego, CA), either at Illumina or in cohort-
specific laboratories, and each cohort conducted its own quality control and normalization of data, 
as described in Supplementary Data. Since the PACE consortium has observed that extreme outliers 
(greater than three times the interquartile range) can have a large impact on results, they were 
removed prior to analyses. For all analyses, normalized, untransformed β values were evaluated as 
outcomes. 
Cohort-Specific Statistical Analyses 
Cohorts ran independent EWAS models according to the same analysis plan, using robust linear 
regression, as this method controls for possible heteroscedasticity and potential outliers. Only 
singleton pregnancies were included in analyses. GDM was modeled as the exposure of interest, 
and the cord blood DNA methylation level at each CpG was modeled as the outcome. Regression 
models were adjusted for hypothesized confounders, which included newborn’s sex, maternal age, 
maternal education level, maternal BMI (prepregnancy or early pregnancy), maternal smoking 
status during pregnancy (ever vs. never), and maternal genetic ancestry (if available) or maternal 
race/ethnicity. Cohort-specific details for covariate assessment are described in Supplementary Data. 
First, we adjusted only for this baseline set of covariates (results are presented in Supplementary 
Data), such that results could be compared with previous studies, which have generally not 
accounted for cord blood cell heterogeneity. However, our final model was additionally adjusted for 
cord blood cell fractions, including B cells, CD8+ T cells, CD4+ T cells, granulocytes, natural killer 
cells, monocytes, and nucleated red blood cells, which were estimated using a cord blood reference 
panel (25). We also examined results from two of the larger participating cohorts (PREDO and 
Project Viva) after additional adjustment for parity. Since results were very similar (Supplementary 
Tables 2 and 3), parity was not included in the final model. 
Meta-analyses 
METAL (26) was used to conduct inverse variance–weighted fixed-effects meta-analyses, using 
results from the cohort-specific analyses. Control probes, probes mapping to the X and Y 
chromosomes, and probes that have been shown to cross-hybridize or that target polymorphic CpGs 
or contain single nucleotide polymorphisms (SNPs) at the single base pair (bp) extension (27) were 
excluded. A total of 380,878 CpGs were therefore included in the meta-analyses. Probes were 
annotated to hg19 using the IlluminaHumanMethylation450kanno.ilmn12.hg19 R package (28). 
After meta-analyses were complete, a second analyst ran shadow meta-analyses to rule out potential 
human error. CpGs were considered differentially methylated if the false discovery rate (FDR)–
adjusted P value (PFDR) was <0.05. 
Potential heterogeneity between studies was assessed using the Cochran Q statistic and I2. 
Additionally, leave-one-out meta-analyses (i.e., comparison of results after the sequential removal 
of one cohort and a meta-analysis of the remaining six cohorts) were conducted to evaluate the 
influence of each individual cohort on the results. 
Differentially methylated regions (DMRs) were identified from meta-analysis results by taking the 
intersection of DMRs identified using two different software programs: comb-p (29) and DMRcate 
(30). comb-p identifies regions enriched for low P values, uses the Stouffer-Liptak method to 
correct for autocorrelation, and adjusts for multiple testing using the Sidak correction (29). 
DMRcate calculates two smoothed estimates for each chromosome (one weighted by F statistics 
and one not) and uses a Satterthwaite approximation to compare these estimates; it then adjusts for 
multiple testing using the FDR method (30). These approaches were selected because they can be 
applied to meta-analysis results. Windows of 500 and 1,000 bp were compared for each approach. 
For comb-p, a P value threshold of 1 × 10−3 was used to specify the start of each region, and a 
distance of 200 bp was selected for extending the region. For DMRcate, the default settings were 
used, as recommended (30), and FDR thresholds of 0.05 and 0.01 were compared. 
Sensitivity Analyses 
Since the seven participating cohorts represent different geographic regions and differ in the timing 
of participant recruitment and the criteria used to classify GDM cases, we ran a series of sensitivity 
meta-analyses. We compared meta-analysis results after restricting to 1) cohorts with GDM cases 
identified by selective versus universal screening, 2) cohorts with GDM cases identified using a 
one-step 75-g versus a two-step 100-g OGTT, 3) European versus U.S. cohorts, and 4) cohorts that 
recruited participants prior to 2004 versus after 2004. 
Look-up Analyses 
In an effort to replicate previous findings, a look-up of CpGs previously identified as differentially 
methylated by GDM status was conducted within results from the meta-analyses (both with and 
without adjustment for estimated cell proportions). Relevant studies were identified in PubMed 
using the following search terms: Gestational diabetes AND DNA methylation. We focused on 
studies that 1) were not included in the current meta-analyses, 2) included >10 GDM cases, 3) 
measured DNA methylation in cord blood using the Infinium HumanMethylation450K, 
MethylationEPIC, or HumanMethylation27 BeadChip array, 4) adjusted for multiple testing using 
any method, and 5) provided effect estimates and P values for individual CpGs. Two studies met 
these criteria (9,12). These studies collectively reported a total of 110 differentially methylated 
CpGs, none of which were common. Additionally, nine CpGs within two genes (MEST and NR3C1) 
that were identified as differentially methylated by GDM status in both cord blood and placenta in a 
previous candidate gene study (11), which are represented on the 450K array, were evaluated. Of 
these 119 CpGs, 32 were cross-reactive or polymorphic or the CpG probe contained a SNP at the 




Characteristics of participating studies are shown in Table 1 and Supplementary Table 1. The 
number (%) of GDM cases per study ranged from 12 (7.7%) for INMA to 180 (23.1%) for PREDO. 
The majority of participants were of European ancestry, and approximately half of the newborns 
were male (N = 1,900 [51.7%]). 
Meta-analyses for the Individual CpG Results 
Probe numbers and the level of inflation (λ) for individual cohort results are shown in 
Supplementary Table 4. The λ for the meta-analyses was 1.15. Meta-analysis results are 
summarized in a Manhattan plot (Fig. 1). No CpGs were identified as differentially methylated by 
GDM status based on a PFDR < 0.05, but six were identified based on a PFDR < 0.10 (Table 2). While 
the directions of effect were generally consistent for the Healthy Start Study, INMA, PREDO, 
Project Viva, and the pooled analysis of RHEA/ENVIRONAGE/Piccolipiù, they often differed for 
ALSPAC or GOYA (Table 2). For five of the CpGs, there was not strong evidence of heterogeneity 
(I2 < 10.0, Pheterogeneity > 0.36), but for one CpG (cg11723077), there was evidence of moderate 
heterogeneity (I2 = 38.7, P = 0.13). However, effect estimates were similar across the leave-one-out 
meta-analyses (results shown in Supplementary Fig. 1 and Supplementary Table 5). 
Look-up Analysis Results 
The full look-up analysis results are presented in Supplementary Tables 6 and 7 within the 
Supplementary Data. Of the 87 CpGs examined, 4 were differentially methylated (uncorrected P < 
0.05) in the same direction in the meta-analysis that accounted for cell heterogeneity 
(Supplementary Table 7). These four CpGs (cg01203331, cg03345925, cg08471713, and 
cg20507276) were annotated to a total of seven genes: NOP56, SNORD56, SNORD57, SNORD86, 
ZC3H3, MEOX1, and OR2L13, respectively. However, based on the 87 tests conducted, FDR-
corrected P values exceeded 0.05 for all of the CpGs evaluated. 
DMRs Identified from the Meta-analysis Results 
Using individual CpG results from the meta-analyses, comb-p identified five regions that were 
differentially methylated by GDM status (Supplementary Table 8). comb-p results were the same 
when either a 500 or 1,000 bp window was used. DMRcate identified two DMRs when using an 
FDR threshold of 0.10. One DMR was identified when using the 500 bp window (chr 1: 
248100407–248100614) and the other when using the 1,000 bp window (chr 10: 135341870–
135342620) (Supplementary Table 9). Both of these DMRs overlapped two DMRs that had also 
been identified by comb-p (Table 3). One was located in the promoter region of OR2L13 and was 
also annotated to pseudogene CLK3P2. The second overlapped a CpG island in the gene body of 
CYP2E1. Percent methylation levels in both regions were lower in the GDM case, compared with 
control, group, and effect estimates were generally consistent for the individual CpGs contained 
within each region (Supplementary Fig. 2). DMRcate did not identify any DMRs when using an 
FDR threshold of 0.05. 
Sensitivity Analysis Results 
Results were generally similar for the six CpGs, with a PFDR < 0.10, and also for CpGs within the 
two DMRs identified by comb-p and DMRcate, after restricting to cohorts with GDM cases 
identified by a one-step 75-g OGTT versus a two-step 100-g OGTT or using selective versus 
universal screening. They were also generally similar for U.S. versus European cohorts and for 
cohorts that recruited participants prior to versus after 2004 (Supplementary Figs. 3–5). 
Conclusions 
While previous studies have investigated associations between maternal GDM and newborn DNA 
methylation (8–16), the majority have been small, used lenient or no adjustment for multiple testing, 
did not consider regional methylation differences, and adjusted for a limited number of covariates. 
In particular, few studies have adjusted for cell heterogeneity, an important source of variability in 
DNA methylation (31). Results have been inconsistent between these previous studies, raising 
questions of robustness and reproducibility. The current study therefore conducted meta-analyses of 
EWAS results from seven cohorts (3,677 mother-newborn pairs [317 with GDM]) participating in 
the PACE consortium (19), which examined associations between GDM and cord blood DNA 
methylation, after adjustment for a larger number of potential confounders. We evaluated 
methylation differences at both the regional and individual CpG level. 
Using two dimension reduction approaches (comb-p [29] and DMRcate [30]), we identified two 
regions that are differentially methylated by GDM status. One of the DMRs identified by the meta-
analysis (chr 1: 248100276–248100614) is located in the promoter region of OR2L13, a gene that 
codes for an olfactory receptor (9). Methylation levels in this region were lower in cord blood from 
GDM-exposed, compared with -unexposed, newborns. This finding is consistent with a previous 
study by Quilter et al. (9), which observed lower cord blood methylation levels at a CpG located in 
this DMR (cg20507276) among GDM-exposed newborns. This same CpG has also been identified 
as differentially methylated in both blood and buccal cells from autism spectrum disorder (ASD) 
case versus control subjects (32). While the mechanism by which OR2L13 may contribute to ASD 
is currently unknown, olfactory dysfunction has been associated with more severe social 
impairments among individuals with ASD (32). Since children exposed to maternal GDM in utero 
have a higher risk of developing ASD (6), future investigation into the potential mediating role of 
OR2L13 in GDM-associated ASD is merited. Methylation levels in the second DMR (chr 10: 
135341933–135342560) were also lower in the GDM case, compared with control, group. This 
DMR is located in a CpG island within the gene body of CYP2E1, which codes for an enzyme that 
is highly expressed in the liver and metabolizes ethanol, numerous drugs, and certain protoxicants 
(33). Although, to our knowledge, the CpGs within this DMR have not previously been associated 
with in utero exposure to GDM, increased CYP2E expression has been observed in peripheral blood 
from individuals with type 1 and type 2 diabetes (33). 
In contrast with the DMR results, we did not identify any individual differentially methylated CpGs 
when we used a conservative PFDR threshold of 0.05. When we used a more lenient PFDR threshold 
of 0.10, six individual CpGs (cg00812770, cg11723077, cg22791932, cg17588003, cg11187204, 
and cg10139436) were identified as differentially methylated by GDM status, none of which had 
been identified in the previous studies that we reviewed. Three of these CpGs (cg11723077, 
cg22791932, and cg17588003) were annotated to genes—SYNJ2, ZFPM1, and C17orf87, 
respectively—and a fourth CpG (cg00812770) was located in a long intergenic noncoding RNA 
(LINC01342). The remaining two CpGs were not annotated to any genes, and the potential 
consequences of altered methylation at these loci are currently unclear. 
The 13 CpGs comprising the two DMRs identified by both comb-p and DMRcate were not 
identified as differentially methylated in individual CpG meta-analyses, likely due to the greater 
statistical power of the DMR approaches. Additionally, the six CpGs identified as differentially 
methylated based on a PFDR < 0.10 in the individual CpG analyses were not identified by either 
comb-p or DMRcate. It is possible that these six CpGs are false positives, since they did not reach 
statistical significance after application of a more conservative threshold of PFDR < 0.05. However, 
two of these CpGs (cg11187204 and cg10139436) also resided in intergenic regions that are either 
CpG poor or sparsely represented on the 450K array, which would have precluded their 
identification using regional approaches. 
In our examination of 87 CpGs that have previously been associated with GDM status (9,11,12), 
only 4 were found to be differentially methylated in the same direction in the current meta-analysis, 
based on an uncorrected P < 0.05. Since these previous studies were similarly conducted in 
predominately European populations, differences in race or ethnicity are likely not driving these 
discrepancies. However, some of the prior findings may be false positives due to small sample sizes, 
insufficient control for multiple testing, or a lack of adjustment for important confounding factors, 
such as maternal BMI. Other potential explanations for the lack of replication include differences in 
exclusion criteria and the fact that these previous studies stratified by fetal sex (9) or GDM 
treatment type (11,12), which was not feasible for the current meta-analysis. 
Importantly, the seven cohorts participating in the current meta-analysis represent eight countries 
and multiple time periods. Since the criteria used to classify GDM differ by country and have 
changed across time, the severity of disease among GDM case subjects, and the proportion of 
control subjects with undiagnosed GDM or hyperglycemia, may have varied between cohorts. 
Nevertheless, we did not observe evidence of heterogeneity for the majority of meta-analysis results. 
Furthermore, results were generally similar across a series of sensitivity analyses, which stratified 
cohorts based on geographic location, time, and the criteria used for GDM classification. It is 
therefore possible that there may be a linear relationship between maternal glucose levels and cord 
blood DNA methylation. However, while there is some evidence for this (34), additional studies are 
needed to determine whether maternal glucose is the main mechanism through which GDM alters 
DNA methylation and, if so, whether there is a clear threshold below which maternal glucose does 
not alter cord blood methylation. 
The current study had many notable strengths. By meta-analyzing results from multiple cohorts, we 
were able to increase the statistical power of the study and adjust for a large number of potential 
confounders, including estimated cell fractions. We also used stringent adjustments for multiple 
testing to reduce the chance of identifying false positives. Another strength of the study was the 
evaluation of DMRs (using two different approaches) in addition to individual CpGs. 
However, our meta-analyses also had limitations. First, there may have been an overall 
underestimation of GDM cases, since GDM in several cohorts was diagnosed based on a selective 
approach. This may have resulted in some participants being misclassified as control subjects, 
which would have biased results toward the null. Another important consideration is that regression 
models were adjusted for maternal BMI because it is a risk factor for GDM (35) and may impact 
cord blood DNA methylation (36). However, this may have also biased results toward the null, 
since GDM in several cohorts was diagnosed selectively based on traditional risk factors, including 
obesity. Importantly, women with GDM may have utilized different strategies to manage their 
disease. However, this information was not available for all cohorts, and the number of GDM case 
subjects adhering to particular management strategies or treatments was very small for most cohorts, 
so these differing subsets of GDM case subjects could not be evaluated separately. We also could 
not evaluate potential differences by fetal sex due to the small number of GDM case subjects per 
cohort. Additionally, since the gestational age at OGTT was not available for all participants, we 
were unable to adjust for this covariate. Another potential limitation was our focus on cord blood 
DNA methylation, which may not reflect methylation patterns in other tissues. However, cord blood 
DNA methylation has been associated with several outcomes that have been associated with in 
utero exposure to GDM, such as early childhood weight and adiposity (37) and ASD (38). While we 
excluded CpGs that overlapped SNPs and also CpG probes with SNPs at the single bp extension 
(27), we cannot rule out the possibility that some of the differentially methylated CpGs and regions 
identified in this meta-analysis may be driven by genetic, rather than epigenetic, differences 
between GDM case and control subjects, which merits future investigation. Finally, since the 
majority of individuals in the seven participating cohorts were of European ancestry, results from 
the current meta-analysis may not be generalizable to other populations. 
Conclusion 
In a meta-analysis of integrated EWAS results from seven pregnancy cohorts, comprising data from 
3,677 mother-newborn pairs, GDM was associated with lower cord blood methylation levels within 
the promoter region of OR2L13 and the gene body of CYP2E1. Given that reduced methylation in 
the OR2L13 promoter has previously been associated with both GDM status and ASD, its potential 
role in mediating this relationship should be evaluated in future studies. Additionally, since 
CYP2E1 is upregulated in peripheral blood from individuals with type 1 and type 2 diabetes, the 
impact of reduced methylation within this gene among GDM-exposed newborns on subsequent 
health merits future investigation. Finally, the inability to replicate many results from previous 
studies of GDM exposure and cord blood DNA methylation highlights the importance of 
conducting EWAS meta-analyses using data from multiple cohorts. 
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